Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
A phase 2 trial of Belzutifan, Fulvestrant, Everolimus and Exemestane in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Overview
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) is a phase 2 interventional study registered as NCT06428396 by Merck Sharp & Dohme LLC, with 120 participants enrolled, started 2024-11-27 and due to reach its primary completion in 2027-05-05. Interventions recorded: Belzutifan, Fulvestrant, Everolimus and Exemestane.
Similar pages
not linked directly; found by shared links- TrialSirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
Shares Exemestane, Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Shares Belzutifan, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Shares Exemestane, Fulvestrant, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialExtension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Shares Belzutifan, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Shares Belzutifan, Merck & Co. (MSD) and the tag pipeline.
- TrialPhase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Shares Exemestane, Everolimus, Fulvestrant and the tag pipeline.